Abstract
Cancer is caused by mutations in oncogenes and tumor suppressor genes, resulting in the deregulation of processes fundamental to the normal behavior of cells. The identification and characterization of oncogenes and tumor suppressors has led to new treatment strategies that have significantly improved cancer outcome. The advent of next generation sequencing has allowed the elucidation of the fine structure of cancer genomes, however, the identification of pathogenic changes is complicated by the inherent genomic instability of cancer cells. Therefore, functional approaches for the identification of novel genes involved in the initiation and development of tumors are critical. Here we report the first whole human genome in vivo RNA interference screen to identify functionally important tumor suppressor genes. Using our novel approach, we identify previously validated tumor suppressor genes including TP53 and MNT, as well as several novel candidate tumor suppressor genes including leukemia inhibitory factor receptor (LIFR). We show that LIFR is a key novel tumor suppressor, whose deregulation may drive the transformation of a significant proportion of human breast cancers. These results demonstrate the power of genome wide in vivo RNAi screens as a method for identifying novel genes regulating tumorigenesis.
Similar content being viewed by others
References
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037
Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Greenman C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158
Elenbaas B et al (2001) Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 15:50–65
Ince TA et al (2007) Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12:160–170
Westbrook TF et al (2005) A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837–848
Malkin D et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238
Prosser J, Thompson AM, Cranston G, Evans HJ (1990) Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5:1573–1579
Hurlin PJ et al (2003) Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis. EMBO J 22:4584–4596
Toyo-oka K et al (2006) Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression. Cancer Res 66:5565–5573
Echeverri CJ et al (2006) Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 3:777–779
Man D et al (2003) Solution structure of the C-terminal domain of the ciliary neurotrophic factor (CNTF) receptor and ligand free associations among components of the CNTF receptor complex. J Biol Chem 278:23285–23294
Wang L, Tu Z, Sun F (2009) A network-based integrative approach to prioritize reliable hits from multiple genome-wide RNAi screens in Drosophila. BMC Genomics 10:220
Kritikou EA et al (2003) A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 130:3459–3468
Zender L et al (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135:852–864
Zhao H et al (2004) Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523–2536
Bric A et al (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16:324–335
Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT (2009) In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat Genet 41:1133–1137
Schlabach MR et al (2008) Cancer proliferation gene discovery through functional genomics. Science 319:620–624
Silva JM et al (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319:617–620
Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Radvanyi L et al (2005) The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 102:11005–11010
Richardson AL et al (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121–132
Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
Sorlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423
Turashvili G et al (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55
Bittner M (2005) International genomics consortium expression project for oncology (expO). Breast samples. https://expo.intgen.org/expo/public/
Chen X et al (2002) Gene expression patterns in human liver cancers. Mol Biol Cell 13:1929–1939
Wurmbach E et al (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45:938–947
Kaiser S et al (2007) Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8:R131
Ki DH et al (2007) Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 121:2005–2012
Su LJ et al (2007) Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 8:140
Stearman RS et al (2005) Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167:1763–1775
Acknowledgments
The authors wish to thank Dr. Tan Ince for providing the HME and HMLE cell lines used in this study. This study was supported in part by grant BC096628 from the DOD, US Congressionally Directed Medical Research Program (to EI).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Elizabeth Iorns, Toby M. Ward contributed equally to this study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Iorns, E., Ward, T.M., Dean, S. et al. Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Res Treat 135, 79–91 (2012). https://doi.org/10.1007/s10549-012-2068-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-012-2068-7